In 2024, Amneal Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Amneal Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 40,500a | 40,600a | 41,900a | |
Total Scope 2 | ||||
Location-Based | 102,400a | 102,100a | 101,700a | |
Total Scope 3 | N/A | N/A | N/A | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 14.4956a | 16.9618a | 18.9395a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Amneal Pharmaceuticals amounted to 142,900 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Amneal Pharmaceuticals increased by 0.14%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2024, the total Scope 1 emissions of Amneal Pharmaceuticals were 40,500 metric tons of CO₂ equivalent (tCO₂e).a
Since 2022, Amneal Pharmaceuticals's Scope 1 emissions have decreased by 3.34%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2023), Amneal Pharmaceuticals's Scope 1 emissions remained relatively stable, indicating that Amneal Pharmaceuticals's emissions have plateaued with no significant change in its operational footprint.a
In 2024, Amneal Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 102,400 tCO₂e using the location-based method.a
Since 2022, Amneal Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have remained relatively stable, indicating that Amneal Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
Compared to the previous year (2023), Amneal Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Amneal Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2024, Amneal Pharmaceuticals reported its Scope 2 emissions using the location-based method.a
In 2024, Amneal Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 40,500 tCO₂e and total revenues of USD 2,794 millions. This translates into an emissions intensity of 14.5 tCO₂e per millions USD.a
In 2024, Amneal Pharmaceuticals reported a Scope 1 emissions intensity of 14.5 tCO₂e per millions USD. Compared to the peer group median of 13.95, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Amneal Pharmaceuticals ranked 12 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Amneal Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a